bluebird bio, Inc. (BLUE)-- I know I lecture onnot buying in the pre.... but if you have the ability to I would. NasdaqGS - NasdaqGS Real Time Price. 7.65+0.28 (+3.80%) At close: November 29 04:00PM EST 7.91 +0.26 (+3.40%)<------------ Pre-Market: 07:12AM EST BUY BLUE $7.80
BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY I have never seen this in all my years of Bio Investing.-! It seems wrong ! bluebird bio Sells Priority Review Voucher for $102 Million Wed, November 30, 2022, 7:00 AM In this article: BLUE +3.80% Watchlist Pattern Bullish - Non-dilutive capital meaningfully strengthens Company’s financial position - SOMERVILLE, Mass., November 30, 2022--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million. bluebird was granted two PRVs upon the US Food and Drug Administration (FDA) approvals of ZYNTEGLO® (betibeglogene autotemcel) for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and SKYSONA® (elivaldogene autotemcel) for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively. "With the sale of our first priority review voucher, we have significantly strengthened our financial outlook," said Andrew Obenshain, chief executive officer, bluebird bio. "As momentum builds across our business, this non-dilutive capital further bolsters the ongoing launches of our two recently approved gene therapies and the execution of near-term, value-creating milestones, including the planned submission and subsequent FDA review of our biologics licensing application for lovo-cel for sickle cell disease." bluebird will receive a payment of $102 million upon closing of the transaction, which remains subject to customary closing conditions, including anti-trust review. The Company continues to explore additional financing opportunities, including the monetization of its second PRV, and anticipates providing full year 2023 guidance early next year.
You get a priority review voucher and then sell it for a different product under review????? Honestly this is crazy and opens up a totally new door for Bio investing who else got these vouchers??? I mean at $100 mln each and BLUE has 1 more to SELL!!!!! OMG. This is not what the FDA had in mind....
Uhhh --- Who's trying to find a little mistake? I wrote $8.15 and you called me a liar with: "Quit lying, you know we got in at $7.90." -case closed.
I'm in Christmas mode now folks! I'm going to take you down a path of massive wealth formation or loss.... Ride with me and ride in style. MAKE THIS YOUR CHRISTMAS 6 PACK----- HOLD THRU X-MAS!! (w/entry price) A)PRVB Provention Bio, Inc. $7.95 B)EE Excelerate Energy, Inc. $27.50 C)WBA Walgreens Boots Alliance, Inc. $40.60 D)CAE CAE Inc. $21.43 E)BLUE $7.90 Man U.XXXXXXXXXXX SOLD $22.30 GO VAN! $17.50---->$22.30 F)MRTX $88.00 ALSO)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) YY @$27 LKRX @$2.00 SIG @$42 BEEM @$16.60 GTLB @$38.70